Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma
- 14 September 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (18) , 5923-5930
Abstract
Purpose: Immunocytokine (IC) hu14.18-IL2 is a fusion protein of humanized antidisialoganglioside (GD2) antibody (hu14.18) and interleukin (IL)-2. Sixty-one melanoma and neuroblastoma patients received IC in phase I/Ib studies. Patient sera were examined in ELISA to determine if an anti-IC antibody response occurred during treatment. Experimental Design: Serum was assayed for anti-idiotypic antibody (anti-id Ab) based on ability to bridge biotinylated hu14.18 to plate-bound hu14.18 and ability to inhibit binding of hu14.18 to GD2 antigen and/or murine anti-idiotypic antibody. ELISA was also used to detect antibodies to the Fc-IL2 end of hu14.18-IL2. Results: Thirty-two patients (52%) developed an anti-idiotypic antibody response (absorbance, >0.7) in the bridge ELISA. Twelve patients (20%) had an intermediate response, whereas 17 patients (28%) were negative (adsorbance, P < 0.002) with IC measured during the second course of treatment, indicating that development of anti-idiotypic antibodies interfered with detection of circulating hu14.18-IL2. All patients developed some inhibitory activity in the binding inhibition assay designed to detect antibodies to the Fc-IL2 region of the IC. There was a positive correlation between the peak serum level of IC in course 1 and the anti–Fc-IL2 response. Conclusions: Patients treated with hu14.18-IL2 developed anti-idiotypic antibodies and anti Fc-IL2 antibodies. No association was seen between development of anti-IC antibodies and clinical toxicity. (Clin Cancer Res 2009;15(18):5923–30)Keywords
This publication has 30 references indexed in Scilit:
- A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology GroupClinical Cancer Research, 2006
- Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma PatientsJournal of Clinical Oncology, 2004
- Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine2003
- A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.2002
- Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphomaBritish Journal of Haematology, 2002
- An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.Proceedings of the National Academy of Sciences, 1996
- Systemic Interleukin-2 Modulates the Anti-Idiotypic Response to Chimeric Anti-GD2 Antibody in Patients with MelanomaJournal of Immunotherapy, 1996
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.Journal of Experimental Medicine, 1996
- Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.Proceedings of the National Academy of Sciences, 1992
- Serum CD25 Levels During Interleukin-2 TherapyJournal of Immunotherapy, 1992